Management of patients with myocardial infarction and hypertension

Lip, Gregory Y.H.; Lydakis, Charalampos; Beevers, D. G.

doi:10.1053/euhj.1999.2206

Cited by 7 publications

(4 citation statements)

References 69 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Accordingly, we used a glucose level of greater than 140 mg/dl as the cut-off level for fasting glucose, as some of the earlier studies do [10]. In addition, the acute coronary event may be accompanied by elevated blood pressure either because of acute stress or secondary to previous hypertension or hypotension, mostly because of marked reduction in cardiac output as a result of extensive infarction [24]. As the blood pressure obtained in the acute phase of MI may not be representative of a patient's true blood pressure level, patients reporting a history of hypertension and patients under antihypertensive therapy were defined as having hypertension regardless of the blood pressure value measured on admission.…”

Section: Months After Acute Myocardial Infarctionmentioning

confidence: 98%

Impact of metabolic syndrome on future cardiovascular events in patients with first acute myocardial infarction

Selçuk¹,

Temizhan²,

Selçuk³

et al. 2009

Coronary Artery Disease

View full text Add to dashboard Cite

The prevalence of metabolic syndrome (MetS) is increasing worldwide and patients with MetS have increased risk of cardiovascular events. Recent studies in different populations showed higher prevalences of MetS in patients with acute myocardial infarction (MI) and identified MetS as an independent predictor of future cardiac events. This study sought to determine the prevalence of MetS in patients with acute MI and investigate the impact of MetS on adverse cardiovascular events after acute MI. One hundred and eighty-eight patients (155 men, 33 women) admitted with first acute MI were enrolled into the study. Of the total patients, 80 (42.6%) patients were diagnosed with MetS according to the National Cholesterol Education Program Adult Treatment Panel III criteria with modifications for high blood pressure and high fasting plasma glucose. Kaplan-Meier curves showed that the cumulative event-free survival rates did not differ between the patients with and without MetS during a median follow-up period of 27.7 (min:14, max:42) months (P>0.05). On multivariate Cox regression analysis controlling for hypertension, diabetes mellitus, glucose, MetS, and waist-to-hip ratio, there was no association between the major adverse coronary events and the presence of MetS (P>0.05), whereas Killip class (relative risk: 2.853, 95% confidence interval: 1.606-5.070; P<0.001) was identified as the only independent predictor of long-term cardiovascular outcomes. This study shows that MetS has no effect on long-term prognosis after MI. However, Killip class was identified as an independent predictor of major cardiac events.

show abstract

Section: Months After Acute Myocardial Infarctionmentioning

confidence: 98%

Impact of metabolic syndrome on future cardiovascular events in patients with first acute myocardial infarction

Selçuk¹,

Temizhan²,

Selçuk³

et al. 2009

Coronary Artery Disease

View full text Add to dashboard Cite

show abstract

“…In patients with heart failure, previous MI or angina, b-blockers may be an appropriate choice as the third agent [3], since they may help to reduce recurrent MI and mortality through protective actions on the ischemic myocardial tissue and antiarrhythmic properties [101]. CCBs, on the other hand, should be avoided in patients with congestive heart failure unless they are required to control the symptoms of angina [3,5,102].…”

Section: Review | Neutelmentioning

confidence: 99%

Treatment algorithms for hypertension: a practical approach

Neutel¹

2013

Clinical Practice

View full text Add to dashboard Cite

show abstract

“…Thus, although intravenous beta-blockers are not necessarily recommended for all patients, the early treatment of all patients without contraindications with a beta-blocker is strongly supported by evidence and guidelines. There is compelling evidence that beta-blocker as secondary prevention reduces the risk of all cause mortality, coronary mortality, recurrent non-fatal myocardial infarction and sudden death in patients [56]. This is manifest clinically from large scale trials utilising beta blocker within hours or days [57].…”

Section: Beta-blocker In Acsmentioning

confidence: 99%

Management of Hypertension in Relation to Acute Coronary Syndromes and Revascularisation

Kühl¹,

Lip²,

Varma³

2007

CPD

View full text Add to dashboard Cite

In patients with acute coronary syndromes (ACS), hypertension is common. The type of ACS and severity of hypertension would determine the treatment algorithm. In ST elevation myocardial infarction (MI), time to reperfusion is essential whereas in malignant hypertension the reduction of blood pressure to prevent end organ damage is the priority. Many therapeutic drugs available for ACS and hypertension are commonly used to treat both these conditions simultaneously. Once the ACS is treated medically, revascularization therapy is likely to be considered. Importantly, optimization of hypertension management may prevent subsequent complications. In this review, we discuss the frequency of hypertension and ACS as single clinical conditions, as well as combined presentations. The pathophysiology of myocardial perfusion in hypertensive patients and the effect of blood pressure (BP) normalization is discussed. This review focuses on treatment strategies from a non-interventional and interventional perspective. Finally, current medications used in treating hypertension in ACS will be compared with regards to their mode of action and prognostic value.

show abstract

Management of patients with myocardial infarction and hypertension

Cited by 7 publications

References 69 publications

Impact of metabolic syndrome on future cardiovascular events in patients with first acute myocardial infarction

Impact of metabolic syndrome on future cardiovascular events in patients with first acute myocardial infarction

Treatment algorithms for hypertension: a practical approach

Management of Hypertension in Relation to Acute Coronary Syndromes and Revascularisation

Contact Info

Product

Resources

About